These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 20206975)

  • 21. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
    Akimoto S; Inomiya H; Furuya Y; Akakura K; Ito H
    Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
    Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK
    Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
    Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
    J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
    Lorente JA; Valenzuela H; Morote J; Gelabert A
    Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
    Mikah P; Krabbe LM; Eminaga O; Herrmann E; Papavassilis P; Hinkelammert R; Semjonow A; Schrader AJ; Boegemann M
    BMC Cancer; 2016 Mar; 16():214. PubMed ID: 26975660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
    Nozawa M; Hara I; Matsuyama H; Iki M; Nagao K; Nishioka T; Komura T; Esa A; Uejima S; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uemura H
    World J Urol; 2015 Sep; 33(9):1263-8. PubMed ID: 25354720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features and prognostic factors for patients with bone metastases from prostate cancer.
    He J; Zeng ZC; Yang P; Chen B; Jiang W; Du SS
    Asian J Androl; 2012 May; 14(3):505-8. PubMed ID: 22504872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
    Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
    Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
    Han KS; Hong SJ
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1769-76. PubMed ID: 24858569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
    Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
    Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
    Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
    Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients.
    Imamura M; Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Sakita I; Hatada T; Takatsuka Y; Katagiri T; Miyoshi Y
    Breast Cancer Res Treat; 2015 Dec; 154(3):521-31. PubMed ID: 26573829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.